Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Session Type:

Participation Type:

HIVR4P Home

HIVR4P 2016 is made possible in part by the generous support of the American people through 1 R13 AI122959-01 from the National Institute of Allergy and Infectious Diseases (NIAID), and from the United States Agency for International Development (USAID). The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services or USAID; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

  • Sort by:
  • Browse by:
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 sessions: 1 to 14 of 14 from HIV Research for Prevention 2016
Round Table 03: Combinations and Keys: The Complexities and Successes of Reaching the People Who Need It
HIV and Sex Workers: Challenges and Lessons for Scaling up Programmes
Sinead Delany-Moretlwe
University of the Witwatersrand, South Africa
Reaching Epidemic Control by 2030: Challenges and Opportunities for Adolescent Girls and Young Women in Kenya
Kawango Agot
Impact Research & Development Organization, Kenya
Finding the Right Fit: Combination HIV Prevention for Men Who Have Sex with Men
Hyman Scott
San Francisco Department of Public Health, United States
Understanding HIV Risk Among Transgender Women and Developing Interventions for this Vulnerable Population
Amy Johnson
Ann & Robert H. Lurie Childrens Hospital of Chicago, United States
The Complexities and Successes of Reaching the People Who Inject Drugs
John Brooks
Centers for Disease Control and Prevention, Division of HIV/AIDS Prevention, United States
Round Table Discussion: Combinations and Keys: The Complexities and Successes of Reaching the People Who Need It
Sinead Delany-Moretlwe
University of the Witwatersrand, South Africa
Kawango Agot
Impact Research & Development Organization, Kenya
Hyman Scott
San Francisco Department of Public Health, United States
Amy Johnson
Ann & Robert H. Lurie Childrens Hospital of Chicago, United States
John Brooks
Centers for Disease Control and Prevention, Division of HIV/AIDS Prevention, United States
from HIV Research for Prevention 2016 on 20 October 2016 08:30-10:00
Round Table 04: Getting It Right: The Journey from Discovery to Impact
When We Got It Right and When We Got It Wrong
Maggie Keane
International AIDS Vaccine Initiative, United States
From Research to Practice: Translating VMMC Market Research into Program Design and Implementation in Zimbabwe
Karin Hatzold
Population Services International, Zimbabwe
Female Condoms: The World's Second HIV Prevention Tool—Barriers to a Good Product Getting Promoted and Used
Anne Philpott
Department for International Development, United Kingdom
Planning for Delivery: The Power of Partnerships (PMTCT: Thailand experience)
Rangsima Lolekha
Thailand MOPH - U.S. CDC Collaboration, Thailand
Round Table Discussion: Getting It Right: The Journey from Discovery to Impact
Maggie Keane
International AIDS Vaccine Initiative, United States
Karin Hatzold
Population Services International, Zimbabwe
Anne Philpott
Department for International Development, United Kingdom
Rangsima Lolekha
Thailand MOPH - U.S. CDC Collaboration, Thailand
from HIV Research for Prevention 2016 on 20 October 2016 08:30-10:00
Symposium 07: Entering the Dark Zone: Germinal Centers in Immune Response
Role of Adjuvants in Enhancing Durability of HIV Vaccine Responses by Inducing Potent Germinal Centers and Plasma Cell Responses
Sudhir Kasturi
Emory University, United States
The Many Flavors of Vaccine-Induced CD4 T Cell Responses
Hendrik Streeck
Institute for HIV Research, Germany
B Cell Follicle Sanctuary Permits Persistent Productive SIV Infection in Elite Controllers: Implications for HIV Cure
Afam Okoye
Oregon Health & Science University, United States
Selection Dynamics in the Germinal Center during Antibody Affinity Maturation
Alexander Gitlin
Rockefeller University, United States
from HIV Research for Prevention 2016 on 20 October 2016 08:30-10:00
Symposium 08: Envelope Structure and Broadly Neutralizing Antibodies
Structural Dynamics of HIV Env Glycoproteins: A Link between Structural, Functional, and Phenotypic Variation among Isolates
Kelly Lee
University of Washington, United States
The HIV Glycan Shield as a Target for Broadly Neutralizing Antibodies
Katie Doores
King's College London, United Kingdom
Immunogenicity of Multiple SOSIP Trimers in Different Animal Species
John Moore
Weill Medical College, United States
Broadly Neutralizing Antibody Lineages and Precursors
Penny Moore
University of the Witwatersrand, South Africa
from HIV Research for Prevention 2016 on 20 October 2016 08:30-10:00
Oral Abstract Session 17: Cellular Immunity Matters!
Programming T and B Cell Homing to Mucosal Sites to Induce Protective and/or Therapeutic Vaccination Using Chemokine-adjuvanted DNA Plasmids
Yoann Aldon
Imperial College London, United Kingdom
Mucosal Administration of Particulate Antigens Improves TFH Generation, HIV-specific High-quality and Long-lasting Immunity
Thomas Vazquez
I3 Laboratory - UPMC/INSERM UMRS959, France
Vaccine-induced CD8+ T Cell Immunity Strongly Predicts Lower HIV Infection Risk in HVTN 505
Holly Janes
Fred Hutchinson Cancer Research Center, United States
Induction of Unique Subset of Follicular Homing SIV-specific CD8 T Cells by Vaccination Is Associated with Enhanced Control of Pathogenic SIV
Rama Amara
Emory University, United States
Restoration of Defective T Cell Priming and Polarization in BLT Humanized Mice through Systemic Administration of IL-12p70
Daniel Claiborne
Ragon Institute of MGH, MIT and Harvard, United States
Antiviral CD8+ T Cells Restricted by HLA Class II DRB1 Exist in HIV Infection and Exhibit Clonal Expansion
Srinika Ranasinghe
Ragon Institute of MGH, MIT and Harvard, United States
from HIV Research for Prevention 2016 on 20 October 2016 10:30-12:00
Oral Abstract Session 18: The Great Escape: Host-Virus Transmission Dynamics
Gender Differences in Transmission of HIV-1 Viral Variants and Their Impact on Early Immune Activation
Elina El-Badry
Emory University, United States
Infant Peripartum Transmitted-founder HIV-1 Variants are Resistant to Autologous Maternal Plasma Neutralization
Amit Kumar
Duke Human Vaccine Institute, United States
Transmission of Multiple HIV-1 Founder Viruses and High Frequency of Unique Recombinant Forms among MSM in Kenya
Gladys Macharia
Kenya Medical Research Institute
Higher HIV-1 Envelope Sequence Diversity in the Vaginal Tract than in Blood at Early Stage of Infection
Katja Klein
University of Western Ontario, Canada
CD8+ T Cell Dynamics in Untreated and Treated Hyperacute HIV Infection; Implications for HIV Vaccines and Cure Strategies
Zaza Ndhlovu
University of KwaZulu Natal, South Africa
Localization of the First Infected Cells after Oral Viral Exposure in Infant Maqcues
Michael McRaven
Northwestern University, United States
from HIV Research for Prevention 2016 on 20 October 2016 10:30-12:00
Oral Abstract Session 19: Passive Immunization: Instant Protection
Rational Design of Bispecific Antibodies Targeting HIV-1 Env to Achieve Enhanced Anti-viral Potency and Breadth
James Steinhardt
Institute for Bioscience and Biotechnology Research, United States
Partial Efficacy of a Broadly Neutralizing Antibody against Cell-associated SHIV Infection
Stephen Kent
University of Melbourne, Australia
Durable Marked Attenuation and Clearance of SHIV Infection in Infant Macaques with Human Neutralizing mAbs as Post-exposure Treatment Within 48 Hours
Ann J. Hessell
Oregon Health & Science University, Oregon National Primate Research Center, United States
Virus Fitness after Infusion with Broadly Neutralizing Antibody VRC01
Rebecca Lynch
The George Washington University, United States
Rectal and Vaginal Biopsies from Men and Women Infused Intravenously with VRC01 Show Protection in Ex Vivo HIV-1 Challenge
Rena D. Astronomo
Fred Hutchinson Cancer Research Center, United States
Variable IgG Transplacental Transfer in the Setting of Maternal HIV Infection
David R. Martinez
Duke Human Vaccine Institute, United States
from HIV Research for Prevention 2016 on 20 October 2016 10:30-12:00
Oral Abstract Session 20: Trust But Verify: Understanding Adherence
High Levels of Adherence to a Rectal Microbicide Gel and to Oral PrEP Achieved in MTN-017
Alex Carballo-Diéguez
HIV Center for Clinical and Behavioral Studies at New York State Psychiatric Institute and Columbia University, United States
Vaginal Ring Use in a Phase 3 Microbicide Trial: A Comparison of an Objective Measure of Adherence in ASPIRE with Self-reports of Product Use
Barbara S. Mensch
Population Council, United States
Frequency of Partner-related Social Harms and their Impact on Adherence to the Dapivirine Vaginal Ring during the MTN020/ASPIRE HIV Prevention Trial
Thesla Palanee-Phillips
Wits Reproductive Health and HIV Institute, South Africa
Can Infrared Spectroscopy (IR) Coupled with Chemometrics Be Used for Objective Measure of Adherence to Microbicide Products?
Oluwatosin Adedipe
CONRAD, Eastern Virginia Medical School, United States
Novel Implementation of a Real-time Adherence Monitoring Strategy within a Phase III, Blinded, Placebo-Controlled, HIV-1 Prevention Clinical Trial
Marla J. Husnik
Fred Hutchinson Cancer Research Center, United States
Clinical Assessment of New Objective Measures of Adherence for Four Placebo Vaginal Dosage Platforms
Terry Jacot
CONRAD, Eastern Virginia Medical School, United States
from HIV Research for Prevention 2016 on 20 October 2016 10:30-12:00
Oral Abstract Session 21: Designer Envelopes for Fashionable Responses
Characterization of Transmitted/Founder CRF01_AE Virus Envelope Trimers from the RV217-early Capture HIV Cohort Study
Neeti Ananthaswamy
The Catholic University of America, United States
Targeted Deglycosylation as a Means of Vaccine Focusing
Peter Kwong
Vaccine Research Center, United States
Composition and Antigenic Effects of Individual Glycan Sites of the HIV-1 Glycan Shield
Anna-Janina Behrens
University of Oxford, United Kingdom
Delineating the Conformational Stability of the HIV-1 Envelope Glycoprotein Trimer
Branislav Ivan
University of Zurich, Switzerland
Development of a Soluble HIV-1 Env Trimer Immunogen Stabilized in the Pre-fusion Closed State from Strain CH505
Kai Xu
Vaccine Research Center, NIAID, NIH, United States
Glycan-masking Improves the CD4bs-specificity of Antibodies Elicited by eOD-GT8 60mer
Xuejun Chen
Vaccine Research Center/NIAID/NIH, United States
from HIV Research for Prevention 2016 on 20 October 2016 13:00-14:30
Oral Abstract Session 22: Human Vaccine Clinical Trials: Reality Check
UK HVC 003: A Phase I Clinical Trial Exploring a Strategy to Maximise HIV Antibody Responses using Subtype C DNA, MVA and GLA Adjuvanted gp140
Sarah Joseph
MRC Clinical Trials Unit at UCL, United Kingdom
DNA/MVA HIV Vaccine Producing Virus-like Particles (VLPs) Is Well-tolerated and Induces Durable Functional Antibodies (Abs) in HVTN 094
Susan Buchbinder
San Francisco Department of Public Health, United States
Delayed Boost of ALVAC®HIV and AIDSVAX® B/E gp120 Following the RV144 Regimen, Significantly Increases HIV-1 Neutralizing Antibody Responses
Lindsay Wieczorek
U.S. Military HIV Research Program, United States
Characterization of HIV-1 Envelope Antibody Responses Following ALVAC-HIV and AIDSVAX B/E Prime-boost Vaccinations with Varying Late Boosts (RV306)
Siriwat Akapirat
Armed Forces Research Institute of Medical Sciences, Thailand
Upper Respiratory Tract (URT) Administration of a Replication Competent Ad4-H5-Vtn Vaccine Induces Durable Neutralizing Antibody Responses in Humans
Jinghe Huang
National Institute of Allergy and Infectious Diseases (NIAID), NIH, United States
HIV Vaccine Trials Network (HVTN) 910: Long-term Follow-up of HIV Vaccine-induced Seropositivity (VISP) among HIV Vaccinees
John Hural
HIV Vaccine Trials Network, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, United States
from HIV Research for Prevention 2016 on 20 October 2016 13:00-14:30
Oral Abstract Session 23: Power, Pleasure and Prevention
Happy Clients: A Model for Promoting Long Acting Reversible Contraceptives
Alexandra Hoagland
Zambia Emory HIV Research Project (ZEHRP), Zambia
The Impact of a Randomized Evaluation of a Girl's Empowerment Program on HSV-2 and HIV Acquisition among Vulnerable Adolescent Girls in Zambia
Paul C. Hewett
Population Council, United States
Effectiveness of Integrated HIV Prevention and Family Planning Services for Couples in Zambia to Prevent HIV and Unintended Pregnancy
Mubiana Inambao
Zambia Emory HIV Research Project (ZEHRP), Zambia
HIV Prevention Method Using Life Skills Education Program among In-school Adolescents in South West Nigeria
Olubunmi Fakunle
Public Health Department, Nigeria
The Influence of the Vaginal Ring on Sexual Experiences of Women in an HIV Prevention Clinical Trial
Nicole Laborde
RTI International, United States
Balancing HIV Risk with Fertility Desires and Willingness to Pay for Oral PrEP to Reduce Risks: Findings from a Discrete Choice Experiment
Sheree Schwartz
Johns Hopkins Bloomberg School of Public Health, United States
from HIV Research for Prevention 2016 on 20 October 2016 13:00-14:30
Oral Abstract Session 24: Prevention: Think Global, Prevent Local
Evaluating the Impact of the Voluntary Medical Male Circumcision (VMMC) Program in Kenya
John Stover
Avenir Health, United States
“How I Wish This Thing Was Initiated 100 Years Ago!” Willingness to Take Daily Oral Pre-exposure Prophylaxis among Men Who Have Sex with Men in Kenya
Robinson Karuga
LVCT Health, Kenya
PrEP Uptake and Demographic Characteristics of PrEP Users in Two Large Medical Systems in San Francisco
Susan Scheer
San Francisco Department of Public Health, United States
Prepping 4 Love: Engaging Focus Communities in the Development of a Citywide Social Marketing Campaign
Amy Johnson
AIDS Foundation of Chicago, United States
Studies in Orange Farm, a Township of South Africa, Revealed That Obtaining a Male Circumcision Prevalence Rate of 80% Is Difficult but Feasible
Bertran Auvert
INSERM U1018, France
Feasibility of Conducting HIV-combination Intervention Effectiveness Trials in Fishing Communities in Uganda: A Cluster Randomized Pilot
Monica Kuteesa
MRC/UVRI Uganda Research Unit on AIDS, Uganda
from HIV Research for Prevention 2016 on 20 October 2016 13:00-14:30
Rapporteur 01: Rapporteur Session
Lead Rapporteur - Team A
Cynthia Derdeyn
Emory University, United States
Lead Rapporteur - Team B
Raphael Landovitz
UCLA Center for Clinical AIDS Research & Education, United States
Lead Rapporteur - Team C
Barbara Shacklett
University of California, United States
Lead Rapporteur - Team D
Morenike Ukpong
Institute of Public Health, Obafemi Awolowo University; New HIV Vaccine and Microbicide Advocacy Society, Nigeria
from HIV Research for Prevention 2016 on 20 October 2016 15:00-16:30
Closing Plenary: Bring It On: Delivering Combination Prevention
Introduction and Tribute to Ward Cates
Myron Cohen
University of North Carolina, United States
Sexual and Reproductive Health Over a Lifetime: Ward Cates' Contribution
Helen Rees
Wits Reproductive Health and HIV Institute, South Africa
From Research to Implementation: Delivery and Rollout
Deborah Birx
Office of the U.S. Global AIDS Coordinator, United States
Control of the HIV Epidemic: The Requirement for Effective Prevention
Emilio Emini
Bill & Melinda Gates Foundation, United States
Desmond Tutu Award for HIV Prevention and Human Rights
Nelly Mugo
Kenya Medical Research Institute (KEMRI), Kenya
Omu Falobi Award
Manju Chatani
AVAC, United States
Closing Remarks
Jeanne Marrazzo
University of Alabama at Birmingham School of Medicine, United States
Closing Remarks
Lynn Morris
National Institute for Communicable Diseases of the NHLS, South Africa
from HIV Research for Prevention 2016 on 20 October 2016 16:30-18:30
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 sessions: 1 to 14 of 14 from HIV Research for Prevention 2016